Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
Original Article
A. Chari, D.T. Vogl, M. Gavriatopoulou, A.K. Nooka, A.J. Yee, C.A. Huff, P. Moreau, D. Dingli, C. Cole, S. Lonial, M. Dimopoulos, A.K. Stewart, J. Richter, R. Vij, S. Tuchman, M.S. Raab, K.C. Weisel, M. Delforge, R.F. Cornell, D. Kaminetzky, J.E. Hoffman, L.J. Costa, T.L. Parker, M. Levy, M. Schreder, N. Meuleman, L. Frenzel, M. Mohty, S. Choquet, G. Schiller, R.L. Comenzo, M. Engelhardt, T. Illmer, P. Vlummens, C. Doyen, T. Facon, L. Karlin, A. Perrot, K. Podar, M.G. Kauffman, S. Shacham, L. Li, S. Tang, C. Picklesimer, J.-R. Saint-Martin, M. Crochiere, H. Chang, S. Parekh, Y. Landesman, J. Shah, P.G. Richardson, and S. Jagannath
N Engl J Med 2019;381:727-738
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Course closed
This course closed on Sunday, August 22, 2021 - 11:59pm.